WO2018029705A1 - Novel glucose oxidase compositions - Google Patents
Novel glucose oxidase compositions Download PDFInfo
- Publication number
- WO2018029705A1 WO2018029705A1 PCT/IN2017/050332 IN2017050332W WO2018029705A1 WO 2018029705 A1 WO2018029705 A1 WO 2018029705A1 IN 2017050332 W IN2017050332 W IN 2017050332W WO 2018029705 A1 WO2018029705 A1 WO 2018029705A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compositions
- glucose oxidase
- composition
- oligosaccharides
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/30—Artificial sweetening agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/30—Artificial sweetening agents
- A23L27/31—Artificial sweetening agents containing amino acids, nucleotides, peptides or derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/30—Artificial sweetening agents
- A23L27/33—Artificial sweetening agents containing sugars or derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/30—Artificial sweetening agents
- A23L27/33—Artificial sweetening agents containing sugars or derivatives
- A23L27/36—Terpene glycosides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/30—Artificial sweetening agents
- A23L27/33—Artificial sweetening agents containing sugars or derivatives
- A23L27/37—Halogenated sugars
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
- A23L29/37—Sugar alcohols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/03—Oxidoreductases acting on the CH-OH group of donors (1.1) with a oxygen as acceptor (1.1.3)
- C12Y101/03004—Glucose oxidase (1.1.3.4)
Definitions
- the invention relates to compositions which include glucose oxidase enzyme as a primary ingredient, hereinafter referred as glucose oxidase compositions.
- glucose oxidase compositions can further produce various other further compositions such as food compositions, compositions for fortification of food, sweetener compositions, nutraceutical compositions, pharmaceutical compositions etc. hereinafter referred as 'Turther compositions.
- Glucose oxidase compositions have several health benefits for healthy individuals and also individuals suffering from one or more of following:
- hyperglycemia hypoglycemia, weight management challenges, obesity, oxidative stress, hyperuricemia, ketoacidosis, non-ketotic hyperosmolar coma, cardiovascular disease, heart stroke, nephropathy, microalbuminuria, insulin resistance, amyloid foot ulcers, diabetic retinopathy, non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, diabetic macular edema, cataract, glaucoma, High blood cholesterol (HDL) and LDL, triglycerides, atherosclerosis, hypertension, metabolic disorders, constipation, inflammatory bowel disease, ulcerative colitis, Crohn's disease, diverticulitis, neuropathy, coeliac disease, hypothyroidism, hyperthyroidism, polycystic ovarian syndrome, diabetes insipidus, necrobiosis lipoidica diabeticorum, mastopathy, limited joint mobility, frozen shoulder, dupuytren's contracture, trigger finger, carpal
- Glucose oxidase compositions may have from 0.01 95 % of glucose oxidase and an additional ingredient in an amount of at least 5 %.
- the additional ingredient is a carbohydrate.
- carbohydrate is a dietary fibre.
- Carbohydrate may also include arides.
- the dietary fibre includes one or more ingredients from dietary fibres such as one or more of non-starch polysaccharides, methylcellulose, ⁇ -glucans, mucilage, waxes, cyclodextrins, celluloses, hemicelluloses, starches, dextrins, inulins, lignins, chitins, pectins, beta-glucans (from oat bran, whole oats, oatrim or rolled oats, whole grain or dry-milled barley), fibres extracted from legumes, Chitosan, natural gums, xanthan gum, guar gum, gellan gum, tara gum, gum acacia, gum arabic, beta-mannan, locust bean gum (carob), psylium seed husk gum, galactomannan (including fenumannans), glucomannan or konjac, karaya, tragacanth, hexoses, pento
- Powder compositions granule compositions, crystalline compositions, flour compositions, pill, tablet, hard and soft capsule compositions, pellet compositions, powder for oral suspensions, liquid solutions and suspensions and sterile preparations etc,
- the sweetener composition a further composition prepared from glucose oxidase composition includes a low glycemic index nutritive ingredient wherein such compositions can be used in place of sugar or artificial / natural sweetener.
- a low glycemic index nutritive ingredient in such compositions contains at least one ingredient which tastes sweet and hereinafter referred as a sweetening agent.
- the invention relates to a sweetener composition comprising Glucose oxidase (GOD) enzyme in a concentration range of 0.1% - 99.99% by weight of the total composition and at least one low glycemic index nutritive ingredient including one or more of polyols and saccharides. Furthermore, the invention relates to modified sugar, an article of food, a nutraceutical composition, a pharmaceutical composition comprising the Glucose oxidase (GOD) enzyme compositions
- Nutraceutical sweetener compositions are widely known in the art. Several compositions have been developed for modifying the taste; appearance and mouth feel profile of consumables that contain these sweeteners. Natural caloric sugars, such as sucrose, fructose, and glucose are widely used in beverages, food and pharmaceutical industries due to their pleasant taste. While sweeteners such as sucrose impart a desirable taste, it is high on calories and exhibits a lot of disadvantages on health including obesity, cardiovascular diseases and certain serious metabolic disorders. Therefore, there was a need for alternate low-calorie sweeteners with a sugar-like taste.
- compositions available in market also contain artificial sweeteners like saccharine, Aspartame, Sucralose, Acesulfame K, Neotame, Alitame, etc.
- artificial sweeteners like saccharine, Aspartame, Sucralose, Acesulfame K, Neotame, Alitame, etc.
- such low calorie sweeteners exhibit undesirable tastes such as lingering sweetness; bitter after taste for a long time after consumption, metallic taste and such other unpleasant tastes. Due to these reasons, the use of known natural sweeteners in foods or beverages, cause an unbalanced flavour profile or such foods are rendered with unpalatable sensory attributes when such sweeteners are included in their preparation.
- health hazards such as neurotoxicity, renal toxicity, carcinogenicity, and such other which life threatening hazards are also known to be reported when such artificial sweeteners are included in the food compositions.
- These artificial sweeteners are hence regarded as non-nutritive sweeteners.
- artificial sweeteners also suffer from poor stability profile when used in foods and beverages.
- the available compositions are not safe and thus are not recommended, particularly for children and pregnant women.
- artificial sweeteners are intensely sweet, e.g. Sucralose is 600 times sweeter than sugar.
- the available compositions further contain bulking agents in the formulation to balance the sweetness profile.
- the bulking agents often used include dextrose or maltodextrin which have a Glycemic Index which is higher than that of sugar.
- the glycemic index of Dextrose is 100, that of maltodextrin is 110 and whereas the glycemic index of sugar is 65.
- These bulking agents would be absorbed in vivo which is contrary to the purpose of the use of the non-sugar sweeteners. Thus, the inclusion of these bulking agents in the sweetener composition would actually cause more harm to the body than sugar.
- sweetener composition having sugar-like characteristics in terms of taste, wherein the sweetener composition is again low on calories and also has a low glycemic index. Further, there is need to develop a sweetener composition which is free from high glycemic index components and is stable at fluctuations of temperature and pH when used in food and health care composition.
- diabetes is treated either by the administration of drugs belonging to the class of Sulphonylureas, Biguanides, Thiazolidinediones, Meglitinides, Alpha glucosidase inhibitors or by insulin injections or combination thereof.
- the known antidiabetic drugs help stimulating the secretion of active centers in the pancreas attempting to re-equilibrate the insulin balance.
- the deterioration of the active pancreatic islets usually increases and either stronger or higher dosages of these drugs are required. This eventually leads to increased breakdown of the active centers in the pancreas and further administration of an insulin injection is required.
- insulin administration is associated with an increased risk of diabetes-related complications, cancer, in addition to causing large variations in blood sugar concentrations, usually reaching dangerously high levels of prolonged duration.
- other natural sweetener compositions which include polyols exhibit a laxative effect.
- the inventors have developed a sweetener, a nutraceutical and a pharmaceutical composition which is free from high glycemic bulking agents, and have a pH near to neutral, unlike artificial sweeteners.
- the composition not only addresses the drawbacks of the known sweetener compositions, but also mimics the sensory profile of sugar and acts as a sugar modulator taking into consideration, the low Glycemic index and low insulin index requirements (practically nil insulin index) of diabetics and people suffering from obesity, metabolic syndromes, cardiovascular diseases, hypertension and substantial lowering of blood sugar levels and HbAlC values in diabetic individuals.
- the sweetener composition of the invention eliminates the laxative effect observed with the consumption of other known sweetener compositions which contain polyols.
- the sweetener and the nutraceutical composition is therefore highly safe not only for diabetics but also for children and pregnant women. Furthermore, the pharmaceutical composition of the invention is highly effective in controlling blood sugar, oxidative stress, HbAlC values, cholesterol levels, triglyceride levels and several other disease indications.
- the invention relates to glucose oxidase compositions i.e. compositions having glucose oxidase enzyme as a primary ingredient
- Glucose oxidase compositions contain from 0.01 to 95 % of glucose oxidase enzyme.
- the additional ingredients make up at least 5 % of the composition and include one or more of a carbohydrate, polyol or sugar alcohol.
- the additional ingredient is a carbohydrate.
- carbohydrate is a dietary fibre.
- carbohydrate is a saccharide.
- Invention further includes further compositions prepared from glucose oxidase compositions.
- Glucose oxidase compositions are incorporated into further compositions such as food compositions including compositions for fortification of food, sweetener compositions, nutraceutical compositions and pharmaceutical compositions.
- Glucose oxidase compositions and further compositions can be formulated into various solid and liquid dosage forms. For example, they can be given in hard or soft capsule or tabletted into tablets or provided in the form of sachets and kits thereof. Some of the forms include Powder composition, granule compositions, crystalline compositions, pellet, pill, tablet, hard and soft capsule compositions, pellet compositions, powder for oral suspensions, liquid solutions and suspensions and sterile preparation and kits.
- the invention relates to further compositions such as sweetener compositions produced from glucose oxidase compositions.
- sweetener compositions preferably contain at least 10 % of sweetening agent.
- the sweetener compositions are developed as modified sugar. Modified sugars have higher amounts of sweetening agent preferably at least 50 %, more preferably at least 60 % and most preferably at least 70 %.
- the invention relates to further compositions such as food compositions produced from glucose oxidase compositions.
- the glucose oxidase compositions having glucose oxidase and at least one carbohydrate, polyols or sugar alcohols can be used to prepare further food compositions such as biscuits, confectionaries, bakery products, beverages, juices, products made from fruits or vegetables, sauces, jams, jellies, ready to eat foods, ready to cook foods, sweets and deserts etc.
- the preferred additional ingredient is carbohydrate, more preferably dietary fibre.
- the invention relates to further compositions such as nutraceutical compositions produced from glucose oxidase compositions.
- nutraceutical compositions comprise of one or more of digestive enzymes, antioxidants, nucleotides or nucleic acids, vitamins, minerals, essential and non-essential amino acids and branched chain amino acids (BCAA) as well as speciality nutraceuticals like glutathione, Human growth hormone (HGH), N-acetyl cysteine.
- the preferred branched chain amino acids are Leucine, Isoleucine, Valine, Speciality nutraceuticals selected from one or more of Glutathione, Human growth hormone (HGH), N-acetyl cysteine, S Adenosyl L- Methionine (SAMe).
- the invention relates to further compositions such as pharmaceutical compositions produced from glucose oxidase compositions.
- These compositions have pharmaceutical active ingredients useful for treating one or more of hyperglycemia, hypoglycemia, weight management challenges, obesity, oxidative stress, hyperuricemia, ketoacidosis, non-ketotic hyperosmolar coma, cardiovascular disease, heart stroke, nephropathy, microalbuminuria, insulin resistance, amyloid foot ulcers, diabetic retinopathy, nonproliferative diabetic retinopathy, proliferative diabetic retinopathy, diabetic macular edema, cataract, glaucoma, High blood cholesterol (HDL) and LDL, triglycerides, atherosclerosis, hypertension, metabolic disorders, constipation, inflammatory bowel disease, ulcerative colitis, Crohn's disease, diverticulitis, neuropathy, coeliac disease, hypothyroidism, hyperthyroidism, polycystic ovarian syndrome, diabetes insi
- glucose oxidase composition having up to 95 % of glucose oxidase can be added to prepare further pharmaceutical composition having insulin, sulfonylureas, biguanides gliptins etc. Addition of glucose oxidase compositions to anti-diabetic compositions are preferred. Apart from anti-diabetics, glucose oxidase compositions are combined with other medicines such as anti-hypertensives and medicines used for treatment of elevated total cholesterol, LDL, triglycerides, and to elevate HDL cholesterol etc. and also medicines for Alzheimer's symptoms and Parkinson's disease.
- other medicines such as anti-hypertensives and medicines used for treatment of elevated total cholesterol, LDL, triglycerides, and to elevate HDL cholesterol etc. and also medicines for Alzheimer's symptoms and Parkinson's disease.
- the glucose oxidase helps to reduce the dose of medicine and also the frequency and duration of the medicine.
- the invention relates to providing glucose oxidase compositions or further compositions to provide health benefit to individuals for maintaining blood sugar level, cholesterol and triglyceride levels and body weight within normal limit. Further individuals on such treatIER have other health benefit such as high energy levels throughout the day.
- the invention relates to providing health benefit to individuals suffering from one or more of following:
- hyperglycemia hypoglycemia, weight management challenges, obesity, oxidative stress, hyperuricemia, ketoacidosis, non-ketotic hyperosmolar coma, cardiovascular disease, heart stroke, nephropathy, microalbuminuria, insulin resistance, amyloid foot ulcers, diabetic retinopathy, non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, diabetic macular edema, cataract, glaucoma, High blood cholesterol (HDL) and LDL, triglycerides, atherosclerosis, hypertension, metabolic disorders, constipation, inflammatory bowel disease, ulcerative colitis, Crohn's disease, diverticulitis, neuropathy, coeliac disease, hypothyroidism, hyperthyroidism, polycystic ovarian syndrome, diabetes insipidus, necrobiosis lipoidica diabeticorum, mastopathy, limited joint mobility, frozen shoulder, dupuytren's contracture, trigger finger, carpal
- glucose oxidase compositions and further compositions provide large number of benefits to any individual regardless of age, sex, health, fitness status. Even in healthy normal individuals, glucose oxidase compositions and further compositions provide several health benefits such as maintenance of correct blood sugar levels and body weight and boosting energy levels etc.
- the invention relates to glucose oxidase compositions i.e. compositions having glucose oxidase enzyme as a primary ingredient, Glucose oxidase compositions contain from 0.01 to 95 % of glucose oxidase enzyme.
- the additional ingredients make up at least 5 % of the composition and include one or more of a carbohydrate, polyol or sugar alcohol.
- the additional ingredient is a carbohydrate.
- carbohydrate is a dietary fibre.
- carbohydrate is a saccharide.
- an additional ingredient is a polyol or a sugar alcohol selected from one or more of mannitol, xylitol, maltitol, isomalt, inositol, erythritol, lactitol, glycerol (glycerine), sorbitol, arabitol, ribitol, polyglycetol, hydrogenated starch hydrolysates and its derivatives (HSH), threitol, fruitol, iditol, volemitol, lactitol, galactitol, palatinose, palatinit, propylene glycol, reduced isomalto- oligosaccharides, fructooligosaccharide, maltooligosaccharide, reduced xylo- oligosaccharides, reduced gentiooligosaccharides, reduced maltose syrup, reduced glucose syrup, reduced starch sugar and combinations thereof.
- HSH hydrogenated starch hydroly
- an additional ingredient is a saccharide selected from one or more of tagatose, rhamnose, dextrin including cyclodextrin such as - cyclodextrin, ⁇ -cyclodextrin, and ⁇ -cyclodextrin), maltodextrin (including resistant maltodextrins such as Dietary fibersol-2TM), dextran, ribulose, threose, arabinose, xylose, lyxose, allose, altrose, mannose, idose, levulose, hexulose, maltose, invert sugar, isotrehalose, neotrehalose, palatinose or isomaltulose, erythrose, deoxyribose, gulose, idose, talose, erythrulose, xylulose, psicose, turanose, cellulose, cellobiose, starch, pepsicos
- an additional ingredient is a dietary fibre selected from one or more of non-starch polysaccharides, methylcellulose, ⁇ -glucans, mucilage, waxes, cyclodextrins, celluloses, hemicelluloses, starches, dextrins, inulins, lignins, chitins, pectins, beta-glucans (from oat bran, whole oats, oatrim or rolled oats, whole grain or dry-milled barley), fibres extracted from legumes, Chitosan, natural gums, xanthan gum, guar gum, gellan gum, tara gum, gum acacia, gum arabic, beta-mannan, locust bean gum (carob), psylium seed husk gum, galactomannan, glucomannan or konjac, karaya, tragacanth, hexoses, pentoses, resistant starch, plant waxe
- Invention further includes further compositions prepared from glucose oxidase compositions.
- Glucose oxidase compositions are incorporated into further compositions such as food compositions including compositions for fortification of food, sweetener compositions, nutraceutical compositions and pharmaceutical compositions.
- the process may involve either first preparing glucose oxidase composition and adding further ingredients to make further compositions or without first preparing glucose oxidase compositions but directly preparing further compositions by adding all ingredients of glucose oxidase compositions and further ingredients.
- Glucose oxidase compositions and further compositions can be formulated into various solid and liquid dosage forms. For example, they can be given in hard or soft capsule or tabletted into tablets or provided in the form of sachets and kits thereof.
- the components of glucose oxidase composition or further compositions can be present together as a single composition or present as separate components such as in separate sachets. In such cases before consumption, the components are mixed together or added to a third ingredient and consumed.
- This third ingredient can be food ingredient such as juice. Since the overall concept is about taking glucose oxidase composition over a day, it is also possible that the separate components are consumed within a specified time interval preferably not exceeding 12 hrs and preferably not exceeding 6 hrs.
- a nutraceutical composition in a kit form may have glucose oxidase, dietary fibres and vitamins and antioxidants and they are either mixed together and consumed or added to a third ingredient and consumed or are consumed at different times such as breakfast time and a meal time or a meal time and a snack time etc.
- the time period is not more than 12 hrs and preferably not more than 6 hrs.
- glucose oxidase composition contains 4 % of glucose oxidase and 96 % of beta glucan. In another embodiment in table 2, glucose oxidase composition contains 4 % of glucose oxidase and 96 % of mannitol.
- the invention in a second aspect, relates to further compositions such as sweetener compositions produced from glucose oxidase compositions.
- sweetener compositions contain at least 10 % of sweetening agent.
- Table 7 provides sweetener compositions from formulations I to VII having at least 10 % of one or more of sucrose, mannitol, erythritol and tagatose.
- sweetening agent is 15 % and above. Most preferably it is 50 % and above.
- a sweetener composition without dietary fibre containing 6% Glucose oxidase enzyme + 15% Mannitol + 45% Sucrose + 34% Tagatose.
- This sweetener composition tastes just like sugar without any aftertaste.
- This contains glucose oxidase composition having around 28.6 parts of glucose oxidase and 71.4 parts of mannitol.
- This composition in 21 parts is converted into a further sweetener composition by adding 79 parts having 45 % sucrose and 34 % tagatose.
- This composition can also be prepared by directly mixing all ingredients together without first making a separate glucose oxidase composition. In this composition replacing 8 % mannitol with inulin does not affect the sweetness of the composition and such new composition is a sweetener composition according to the present invention.
- the invention relates to further compositions such as food compositions produced from glucose oxidase compositions.
- the glucose oxidase compositions having glucose oxidase and at least one dietary fibre can be used to prepare further food compositions such as biscuits, confectionaries, bakery products, beverages, juices, products made from fruits or vegetables, sauces, jams, jellies, ready to eat foods, ready to cook foods, sweets and deserts etc.
- the glucose oxidase compositions are added to food products such as wheat flour, semolina, maize flour, rice flour and any similar food component to fortify the same with glucose oxidase composition.
- the invention relates to further compositions such as nutraceutical compositions produced from glucose oxidase compositions.
- nutraceutical compositions comprise of one or more of dietary fibre, digestive enzymes, antioxidants, nucleotides or nucleic acids, vitamins, minerals, essential amino acids, non-essential amino acids, branched chain amino acids (BCAA), speciality nutraceuticals selected from one or more of glutathione, Human growth hormone (HGH), N-acetyl cysteine and plant and fruit extracts such as
- pine bark extract D ibose, bilberry Extract, Costus igneus (Insulin Plant) extract, cranberry extract, blueberry extract, Gooseberry Extract, Rosemary Extract, Gymnema Sylvestra, mangosteen extract, pineapple extract, and kiwi extract and combinations thereof.
- the enzymes are one or more of papain, bromelain, Lipase, amylase, Glucoamylase, beta glucanase, Fructosyl Transferase, and combinations thereof.
- the branched chain amino acids include one or more of Leucine, Isoleucine, Valine, Speciality nutraceuticals selected from one or more of Glutathione, Human growth hormone (HGH), N-acetyl cysteine, S Adenosyl L- Methionine (SAMe).
- the invention relates to further compositions such as pharmaceutical compositions produced from glucose oxidase compositions.
- glucose oxidase composition having up to 95 % of glucose oxidase can be added to prepare further pharmaceutical composition having insulin, sulfonylureas, biguanides, gliptins etc.
- glucose oxidase compositions are combined with other medicines such as anti-hypertensives and medicines used for treatment of elevated total cholesterol, LDL, triglycerides, and to elevate HDL cholesterol etc.
- the glucose oxidase will help to reduce the dose of medicine and also the frequency and duration of the medicine.
- the invention relates to providing glucose oxidase compositions or further compositions to provide health benefit to individuals for maintaining blood sugar level, cholesterol and triglyceride levels and body weight within normal limit. Further individuals on such treatment have other health benefit such as high energy levels throughout the day. In yet another aspect, the invention relates to providing health benefit to individuals suffering from one or more of following:
- hyperglycemia hypoglycemia, weight management challenges, obesity, oxidative stress, hyperuricemia, ketoacidosis, non-ketotic hyperosmolar coma, cardiovascular disease, heart stroke, nephropathy, microalbuminuria, insulin resistance, amyloid foot ulcers, diabetic retinopathy, non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, diabetic macular edema, cataract, glaucoma, High blood cholesterol (HDL) and LDL, triglycerides, atherosclerosis, hypertension, metabolic disorders, constipation, inflammatory bowel disease, ulcerative colitis, Crohn's disease, diverticulitis, neuropathy, coeliac disease, hypothyroidism, hyperthyroidism, polycystic ovarian syndrome, diabetes insipidus, necrobiosis lipoidica diabeticorum, mastopathy, limited joint mobility, frozen shoulder, dupuytren's contracture, trigger finger, carpal
- glucose oxidase compositions and further compositions provide large number of benefits to any individual regardless of age, sex, health, fitness status. Even in healthy normal individuals, glucose oxidase compositions and further compositions provide several health benefit such as maintenance of correct blood sugar levels and body weight and boosting energy levels etc.
- the glucose oxidase compositions and further compositions can be provided in the form of sachets filled with powder, granule and crystalline compositions, pills, pellets or granules in capsule or tablets etc.
- the dose will be around 1 - 2 dosage form per day for healthy individuals and 2 - 4 dosage forms per day for an individual suffering from any diseases mentioned hereinbefore.
- sweetener compositions incorporating glucose oxidase compositions are tested on healthy individuals and the corresponding blood sugar levels are evaluated. This data is compared with i) glucose tolerance test and ii) similar test conducted with an artificial sweetener composition having sucralose. The data is as provided under table 21 and reflects that the sweetener compositions of the present invention are safer to use even for healthy individuals as compared to artificial sweeteners.
- the invention in a second aspect, relates to a sweetener composition
- a sweetener composition comprising: Glucose oxidase (GOD) enzyme composition.
- the sweetener composition further includes at least one low glycemic index nutritive ingredient with a glycemic index of less than 70, preferably less than 50
- Such low glycemic index nutritive ingredient is selected from one or more of carbohydrates, polyols and sugar alcohols.
- the carbohydrates are selected from one or more of saccharides and dietary fibres.
- a low glycemic index nutritive ingredient includes a sweetening agent.
- the sweetener composition preferably includes at least 10 % of a sweetening agent of the total composition, more preferably at least 30 % of the of a sweetening agent of the total composition and most preferably at least 50 % of a sweetening agent of the total composition.
- the glucose oxidase composition is present in further compositions in a concentration range of from 0.01% - 99.99% by weight of the total composition.
- glucose oxidase enzyme composition is present in further compositions in amount from 0.01% - 90% by weight of the total composition.
- Glucose oxidase in glucose oxidase composition is from 0.01 - 95 % of the composition.
- the low glycemic index nutritive ingredient may be present as a part of glucose oxidase composition as well as further compositions. When it is present as a part of both the compositions, its concentration may go up to 99.9% by weight of the total composition.
- the sweetener composition of the present invention may have low glycemic index and low calorie and ideal for the hyperglycemic patients so that they can enjoy a normal life style
- the sweetener composition of the present invention can be used exactly like sugar in the same quantity to get the same quality as that of sugar in a variety of foods and processed food products like bakery, confectionery, etc.
- the sweetener composition of the invention mimics the sensory profile of sugar and acts as a sugar modulator.
- the composition is developed keeping in mind low Glycemic index and low insulin index requirements (practically nil insulin index) of diabetics and people suffering from obesity, metabolic syndromes, cardiovascular diseases, hypertension and substantial lowering of blood sugar levels and HbAlC values in diabetics.
- Sweetener composition according to the present invention can be further developed into a modified sugar.
- the modified sugars may contain high amounts of sweetening agent preferably at least 50 %, more preferably at least 60 % and most preferably at least 70 %.
- samples A - D of table 8 are modified sugars having more than 50 % of sweetening agent.
- the invention relates to a modified sugar which includes the Glucose oxidase (GOD) enzyme in a concentration range of from 0.1% - 50% by weight of the total composition, preferably in the range of from 0.1% - 40% and more preferably from 0.1% - 30%.
- GOD Glucose oxidase
- a further embodiment of the invention relates to an article of food which includes food composition is in the form of biscuits, confectionaries, bakery products, beverages, juices, products made from fruits or vegetables, sauces, jams, jellies, ready to eat foods, ready to cook foods, sweets and deserts and food supplements incorporating sweetener compositions.
- the article of food further includes a low glycemic index nutritive ingredient with a glycemic index of less than 70.
- the low glycemic index nutritive ingredient is present in a concentration range of from 0.01% - 99.9 % by weight of the total composition.
- the invention further relates to a nutraceutical composition
- a nutraceutical composition comprising the sweetener composition which includes the glucose oxidase enzyme and at least one low glycemic index nutritive ingredient.
- the Glucose oxidase (GOD) enzyme is present in the nutraceutical composition in a concentration range of 0.01% - 99.99% by weight of the total composition.
- the nutritive ingredient comprised in the nutraceutical composition is a low glycemic index compound with a glycemic index of less than 70.
- the nutritive ingredient is present in a concentration range of 0.01% - 99.9% by weight of the total composition.
- the invention relates to the use of a nutraceutical composition which includes Glucose oxidase (GOD) enzyme for controlling one or more of hyperglycemia, hypoglycemia, weight management challenges, obesity, oxidative stress, hyperuricemia, ketoacidosis, non-ketotic hyperosmolar coma, cardiovascular disease, heart stroke, nephropathy, microalbuminuria, insulin resistance, amyloid foot ulcers, diabetic retinopathy, non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, diabetic macular edema, cataract, glaucoma, managing high-density lipoproteins (HDL) and low density lipoproteins (LDL), triglycerides, atherosclerosis, hypertension, metabolic disorders, constipation, inflammatory bowel disease, ulcerative colitis, Crohn's disease, diverticulitis, neuropathy, coeliac disease, hypothyroidism, hyperthyroidism,
- GOD
- the invention relates to a pharmaceutical composition which includes the active pharmaceutical ingredient, Glucose oxidase (GOD) enzyme and at least one low glycemic index nutritive ingredient with a glycemic index of less than 70.
- GOD Glucose oxidase
- the active pharmaceutical composition contains active pharmaceutical ingredient for controlling one or more of hyperglycemia, hypoglycemia, weight management challenges, obesity, oxidative stress, hyperuricemia, ketoacidosis, non-ketotic hyperosmolar coma, cardiovascular disease, heart stroke, nephropathy, microalbuminuria, insulin resistance, amyloid foot ulcers, diabetic retinopathy, non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, diabetic macular edema, cataract, glaucoma, managing high-density lipoproteins (HDL) and low density lipoproteins (LDL), triglycerides, atherosclerosis, hypertension, metabolic disorders, constipation, inflammatory bowel disease, ulcerative colitis, Crohn's disease, diverticulitis, neuropathy, coeliac disease, hypothyroidism, hyperthyroidism, polycystic ovarian syndrome, diabetes insipidus, necrobiosis lipoidica
- the nutraceutical or the pharmaceutical composition of the present invention promotes regulation of the blood sugar concentrations in non-diabetic individuals as well as heavily diabetic individuals. It is further observed that the composition of the invention when ingested co-acts with the insulin normally present in the body to reduce the blood sugar concentrations by direct oxidation of glucose or by increasing the speed of the entire metabolic carbohydrate degradation process. Thus, the compositions of the invention are useful as a food supplement as they potentiate and enhance the effectiveness of the insulin present in the non- diabetic human body. Moreover, the composition effectively controls the blood sugar levels of individuals who are hyperglycaemic.
- the composition is highly cost effective as compared to conventional antidiabetic compositions available in the market.
- the sweetener composition of the invention provides a more sugar-like temporal profile including sweetness onset and sweetness linger, along with more sugar-like flavour profile.
- the invention relates to a glucose oxidase compositions and further compositions such as sweetener compositions, food compositions, compositions for fortification of food, nutraceutical compositions and pharmaceutical compositions including Glucose oxidase (GOD) enzyme.
- These compositions unless they are food compositions, are administered along with food, before or after food so that glucose is released in the blood and glucose oxidase can act on excess glucose and regulate the same.
- These compositions can also be provided in kits wherein these compositions are provided as one compositions to be taken multiple times or multiple compositions having different components of the compositions of the present invention.
- a kit may contain a sachet of dietary fibres and a sachet of glucose oxidase and a sachet of vitamins. Based on the instructions these sachets are used over a day.
- Glucose oxidase enzyme is chemically identified as .beta.-D-glucopyranose aerodehydrogenase. It is referred to in the Enzyme Handbook, Vol. I (1969) by T. E. Barman with an Enzyme Code as EC 1.1.3.4. It is an enzyme obtained from mycelia of fungi such as Aspergilli, particularly Aspergillus niger and Penicillia and is a flavoprotein which catalyzes the oxidation of glucose to gluconic acid, the molecular oxygen being reduced to hydrogen peroxide.
- a glucose oxidase unit is defined as that quantity of enzyme which will oxidize 1 millimole of B-D-glucose to D-gluconic acid and hydrogen peroxide per minute at pH 5.1 and 35 DEG C. In the presence of excess oxygen, the activity may increase 50-100%.
- the molecular weight of the product obtained from Aspergillus Niger is about 186,000. This enzyme is highly specific for B-D-glucose.
- the glucose oxidase enzyme used in accordance with the present invention is commercially obtained from manufacturers such as Aum Enzymes as Glucozyme 100 and Novozyme under the brand Gluzyme® Mono 10.000 BG.
- the Glucose oxidase (GOD) enzyme is present in a concentration range of from 0.01% to 95% by weight of the total composition.
- total composition means any of the glucose oxidase composition or a further composition.
- the Glucose oxidase (GOD) enzyme is preferably present in the concentration range of from 0.1% to 40% by weight.
- the glucose oxidase enzyme is present in the concentration range of from 0.1% to 30% by weight of the total composition.
- the glucose oxidase enzyme is present in the concentration range of from 0.1% to 20% by weight of the total composition.
- the glucose oxidase enzyme is present in the concentration range of from 1% to 10% by weight of the total composition.
- glucose oxidase enzyme is present in the concentration range of from 1% to 5% by weight of the total composition.
- the glucose oxidase enzyme is present in a concentration of at least 0.01% by weight of the total composition. According to an embodiment, the glucose oxidase enzyme is present in a concentration of at least 1% by weight of the total composition. According to an embodiment, the glucose oxidase enzyme is present in a concentration of at least 5% by weight of the total composition. According to an embodiment, the glucose oxidase enzyme is present in a concentration of at least 10% by weight of the total composition. According to an embodiment, the glucose oxidase enzyme is present in a concentration of at least 20% by weight of the total composition. According to an embodiment, the glucose oxidase enzyme is present in a concentration of at least 30% by weight of the total composition.
- the glucose oxidase enzyme is present in a concentration of at least 40% by weight of the total composition. According to an embodiment, the glucose oxidase enzyme is present in a concentration of at least 60% by weight of the total composition. According to an embodiment, the glucose oxidase enzyme is present in a concentration of at least 80% by weight of the total composition. According to an embodiment, the glucose oxidase enzyme is present in a concentration of at least 90% by weight of the total composition. According to an embodiment, the glucose oxidase enzyme is present in a concentration of at least 95% by weight of the total composition.
- the low glycemic index nutritive ingredient is present in a concentration range of from 0.01% - 99.9% by weight of the total composition.
- the low glycemic index nutritive ingredient is present in a concentration range of from 0.1% to 96% by weight of the composition.
- the low glycemic index nutritive ingredient is present in a concentration range of 1% - 90% by weight of the total composition.
- the low glycemic index nutritive ingredient is present in a concentration range of 1% - 70% by weight of the total composition.
- the low glycemic index nutritive ingredient is present in a concentration range of 1% - 50% by weight of the total composition.
- the low glycemic index nutritive ingredient is present in a concentration range of 1% - 30% by weight of the total composition. According to yet another embodiment, the low glycemic index nutritive ingredient is present in a concentration range of 1% - 15% by weight of the total composition. According to yet another embodiment, the low glycemic index nutritive ingredient is present in a concentration range of 1% - 10% by weight of the total composition. According to yet another embodiment, the low glycemic index nutritive ingredient is present in a concentration range of 1% - 10% by weight of the total composition. According to an embodiment, the low glycemic index nutritive ingredient is either a carbohydrate or a polyol or both.
- the low glycemic index nutritive ingredient used in accordance with the invention is selected from one or more of carbohydrates and polyols or sugar alcohols.
- the carbohydrates are selected from one or more of dietary fibres and saccharides.
- the low glycemic index nutritive ingredient has a glycemic index of not more than 60. More preferably, the low glycemic index nutritive ingredient has a glycemic index of not more than 50.
- dietary fibres which include dietary fibres, saccharides and polysaccharides, which have a low glycemic index are encompassed within the scope of the present invention.
- the dietary fibres used in accordance with the present invention are a portion of food that is resistant to hydrolysis by human digestive enzymes.
- Several carbohydrates having significantly different structures in both composition and linkages fall within the scope of dietary fibres.
- Non-limiting examples of dietary fibres used according to an embodiment of the present invention include one or more of non-starch polysaccharides, methylcellulose, ⁇ -glucans, mucilage, waxes, cyclodextrins, celluloses, hemicelluloses, starches, dextrins, inulins, lignins, chitins, pectins, beta-glucans (from oat bran, whole oats, oatrim or rolled oats, whole grain or dry-milled barley), fibres extracted from legumes, Chitosan, natural gums, xanthan gum, guar gum, gellan gum, tara gum, gum acacia, gum arabic, beta-mannan, locust bean gum (carob), psylium seed husk gum, galactomannan, glucomannan or konjac, karaya, tragacanth, hexoses, pentoses, resistant starch
- Inulin comprise naturally occurring oligosaccharides belonging to a class of carbohydrates known as fructans. They generally are comprised of fructose units joined by ⁇ (2- 1) glycosidic linkages with a terminal glucose unit. Oligosaccharides are saccharide polymers containing typically three to six component sugars. They are generally found either O- or N-linked to compatible amino acid side chains in proteins or to lipid molecules.
- Food sources of dietary fibres include, but are not limited to, grains, legumes, fruits, and vegetables.
- Grains providing dietary fibres include, but are not limited to, oats, rye, barley, wheat.
- Legumes providing dietary fibres include, but are not limited to, peas and beans such as soybeans.
- Fruits and vegetables providing a source of dietary fibre include, but are not limited to, apples, oranges, pears, bananas, berries, tomatoes, green beans, broccoli, cauliflower, carrots, potatoes, celery.
- Plant foods such as bran, nuts, and seeds (such as flax seeds) are also sources of dietary fibres.
- Parts of plants providing dietary fibres include, but are not limited to, the stems, roots, leaves, seeds, pulp, and skin.
- the indigestible animal products such as chitins are also classified as dietary fibres.
- Sources of dietary fibre often are divided into categories such as soluble dietary fibres and insoluble dietary fibres, based on their solubility in water. Both soluble dietary fibres and insoluble dietary fibres are found in plant foods in varying degrees depending upon the characteristics of the plant.
- the dietary fibres used herein may include a single dietary fibre or a plurality of dietary fibres.
- the dietary fibres preferably include at least one of inulins, galactomannan, beta glucan, fibres extracted from legumes, grains, oats, all types of fruits, vegetables and flaxseeds.
- the dietary fibres also include Inulins (Oligofructose) from chicory root, pectin from apples, guava, citrus fruits and sunflower heads.
- Dietary fibres used in accordance with the present invention such inulin and beta glucan are commercially obtained from suppliers such as ADEPT IMPEX PVT. LTD.
- the dietary fibres are present in a concentration range of 0.01% to 99.9% by weight of the total composition. According to an embodiment, the dietary fibres are present in a concentration range of 0. 1% to 90% by weight of the total composition. According to an embodiment, the dietary fibres are present in a concentration range of 0. 1% to 80% by weight of the total composition. According to an embodiment, the dietary fibres are present in a concentration range of 0. 1% to 70% by weight of the total composition. According to an embodiment, the dietary fibres are present in a concentration range of 0. 1% to 60% by weight of the total composition. According to an embodiment, the dietary fibres are present in a concentration range of 0. 1% to 50% by weight of the total composition.
- the dietary fibres are present in a concentration range of 0. 1% to 40% by weight of the total composition. According to an embodiment, the dietary fibres are present in a concentration range of 0. 1% to 30% by weight of the total composition. According to an embodiment, the dietary fibres are present in a concentration range of 0.1% to 20% by weight of the total composition. According to an embodiment, the dietary fibres are present in a concentration range of 0.1% to 10% by weight of the total composition. According to an embodiment, the dietary fibres are present in a concentration range of 0.1% to 5% by weight of the total composition.
- Sugar alcohols also known as polyols, polyhydric alcohols, or polyalcohols, are the hydrogenated forms of the aldoses or ketoses of a sugar are present in the sweetener or the nutraceutical composition of the present invention.
- sugar alcohols can be characterized by the general formula HO-CH2-(CH-OH)n-CH2-OH, wherein n is typically from 1 to 22.
- sugar alcohols have 5 or 6 carbon atoms in their structure, wherein n is 3 or 4, respectively. While sugar alcohols occur naturally, and can be isolated from plants, most often they are obtained by the selective hydrogenation of sugars. An alternative method of producing sugar alcohols is from fermentation of sugars. Sugars generally refer to the aldose or ketose forms of a sugar. Other common sugar alcohols include the monosaccharides erythritol and xylitol and the disaccharides lactitol and maltitol.
- polyol refers to a molecule that contains more than one hydroxyl group.
- a polyol may be a diol, trio, or a tetraol which contain 2, 3, and 4 hydroxyl groups, respectively.
- a polyol also may contain more than four hydroxyl groups, such as a pentaol, hexaol, heptaol, or the like, which contain 5, 6, or 7 hydroxyl groups, respectively.
- the polyol or sugar alcohols are selected from at least one of mannitol, xylitol, maltitol, isomalt, inositol, erythritol, lactitol, glycerol (glycerine), sorbitol, arabitol, ribitol, polyglycetol, hydrogenated starch hydrolysates (HSH), threitol, fruitol, iditol, volemitol, lactitol, galactitol, palatinose, palatinit, propylene glycol, reduced isomalto-oligosaccharides, fructo- oligosaccharide, maltooligosaccharide, reduced xylo-oligosaccharides, reduced gentio-oligosaccharides, reduced maltose syrup, reduced glucose syrup, reduced starch sugar and sugar alcohols or any other carbohydrates capable of being reduced which does not adversely affect
- the polyols or sugar alcohols are preferably selected from at least one of mannitol, xylitol, maltitol, erythritol, inositol, isomalt and glycerol.
- These polyols such as NEOSORB® Sorbitol, LYCASIN® and POLYSORB® maltitol syrup, PEARLITOL® mannitol, SWEETPEARL® maltitol, XYLISORB® xylitol used in accordance with the present invention are commercially available from manufacturers such as Roquette.
- the polyols or sugar alcohols are present in a concentration range of 0.01% to 99.9% by weight of the total composition. According to an embodiment, the polyols or sugar alcohols are present in a concentration range of 0.1% to 90% by weight of the total composition. According to an embodiment, the polyols or sugar alcohols are present in a concentration range of 0.1% to 60% by weight of the total composition. According to an embodiment, the polyols or sugar alcohols are present in a concentration range of 0.1% to 45% by weight of the total composition. According to an embodiment, the polyols or sugar alcohols are present in a concentration range of 0.1% to 30% by weight of the total composition.
- the polyols or sugar alcohols are present in a concentration range of 0.1% to 20% by weight of the total composition. According to an embodiment, the polyols or sugar alcohols are present in a concentration range of 0.1% to 10% by weight of the total composition. According to an embodiment, the polyols or sugar alcohols are present in a concentration range of 0.1% to 5% by weight of the total composition. According to an embodiment, the polyols or sugar alcohols are present in a concentration range of 1% - 5% by weight of the total composition.
- the saccharide is selected from at least one of fructose, glucose, galactose, sucrose, lactose, trehalose, caramel, golden syrup, refiners syrup, blackstrap molasses, maple syrup, honey, sorghum syrup, cane juice, barley malt syrup, coconut palm sugar, brown rice syrup, agave syrup and derivatives thereof.
- Non limiting examples of saccharides include tagatose, rhamnose, dextrin including cyclodextrin such as a-cyclodextrin, ⁇ -cyclodextrin, and ⁇ -cyclodextrin), maltodextrin (including resistant maltodextrins such as Dietary fibersol-2TM), dextran, ribulose, threose, arabinose, xylose, lyxose, allose, altrose, mannose, idose, levulose, hexulose, maltose, invert sugar, isotrehalose, neotrehalose, palatinose or isomaltulose, erythrose, deoxyribose, gulose, talose, erythrulose, xylulose, psicose, turanose, cellulose, cellobiose, starch, pectins such as amylopectin,
- the saccharides are present in a concentration range of 0.1% to 99.9% by weight of the total composition. According to another embodiment, the saccharides are present in a concentration range of 1% to 96% by weight of the total composition. According to another embodiment, the saccharides are present in the concentration range of 1% to 90% by weight of the total composition. According to another embodiment, the saccharides are present in a concentration range of 1% to 80% by weight of the total composition. According to another embodiment, the saccharides are present in a concentration range of 1% to 70% by weight of the total composition. According to another embodiment, the saccharides are present in a concentration range of 1% to 60% by weight of the total composition.
- the saccharides are present in a concentration range of 1% to 50% by weight of the total composition. According to another embodiment, the saccharides are present in a concentration range of 1% to 40% by weight of the total composition. According to another embodiment, the saccharides are present in a concentration range of 1% to 30% by weight of the total composition. According to another embodiment, the saccharides are present in a concentration range of 1% to 20% by weight of the total composition. According to another embodiment, the saccharides are present in a concentration range of 1% to 15% by weight of the total composition. According to another embodiment, the saccharides are present in a concentration range of 1% to 10% by weight of the total composition. According to another embodiment, the saccharides are present in a concentration range of 1% to 5% by weight of the total composition.
- the sweetener composition can include one or more water soluble polysaccharides.
- the water soluble polysaccharides can be sea weed derived polysaccharides, gum Arabic, galactomannan from fenugreek, alginates, and carrageenan.
- the water soluble polysaccharides are preferably present in the concentration range up to 10% by weight of the total composition.
- the saccharides are preferably selected from one or more of glucose, fructose, levulose, hexulose, sucrose, lactose, maltose, fructo- oligosaccharides, starch, dextrin, cellulose, pectin, glycogen, sea weed derived polysaccharides, gum arabic, alginates, carrageenan and galactomannan.
- composition of the present invention comprises further actives selected from at least one of digestive enzymes, antioxidants, nucleotides or nucleic acids, vitamins and minerals.
- the antioxidants include fruit extracts selected from one or more of bilberry extract, cranberry extract, blueberry extract, mangosteen extract, pineapple extract, and kiwi extract.
- the antioxidants are present in the concentration range up to 30% by weight of the total composition.
- the antioxidants are preferably present in the concentration range up to 10% by weight of the total composition.
- the antioxidants are present in a concentration range of at least 0.1% by weight of the total composition.
- the nucleotides are selected from one or more of inosine monophosphate ("IMP"), guanosine monophosphate (“GMP”), adenosine monophosphate (“AMP”), cytosine monophosphate (CMP), uracil monophosphate (UMP), inosine diphosphate, guanosine diphosphate, adenosine diphosphate, cytosine diphosphate, uracil diphosphate, inosine triphosphate, guanosine triphosphate, adenosine triphosphate, cytosine triphosphate, uracil triphosphate, and their alkali or alkaline earth metal salts, and combinations thereof.
- IMP inosine monophosphate
- GMP guanosine monophosphate
- AMP adenosine monophosphate
- CMP cytosine monophosphate
- UMP uracil monophosphate
- inosine diphosphate guanosine diphosphate
- the nucleotides described herein may comprise nucleotide-related additives, such as nucleosides or nucleic acid bases (e.g., guanine, cytosine, adenine, thymine, uracil).
- the nucleotides are present in the concentration range up to 5% by weight of the total composition.
- the nucleotides are preferably present in the concentration range up to 1% by weight of the total composition. According to another embodiment, the nucleotides are present in a concentration range of at least 0.1% by weight of the total composition.
- Vitamins are essential for normal growth and development and also are important for maintaining good health.
- the vitamins used in accordance with the present invention include vitamin A such as retinol, retinaldehyde, retinoic acid, retinoids, retinal and retitonic acid; Vitamin D or calciferol, chloecalciferol, lumisterol, ergo calciferol, dihydrotachysterol; Vitamin E or tocopherol or tocotrienol; Vitamin K or Phylloquinone or Naphthoquinone; Vitamin Bl or Thiamin; Vitamin B2 or Riboflavin; Vitamin B3 or Niacin or Nicotinic acid or nicotinamide; Vitamin B5 or Pantothenic acid; Vitamin B6 or Pyridoxine or Pyridoxal or Pyridoxamine or pyridoxal hydrochloride; Vitamin B7 or Biotin; Vitamin B9 or folic acid or folate; Vitamin B 12 or Cobalamin or cyan
- vitamins may include pseudovitamins such as ubiquinone (coenzyme Q10), pangamic acid, dimethylglycine, taestrile, amygdaline, flavanoids, para- aminobenzoic acid, adenine, adenylic acid, and s-methylmethionine.
- pseudovitamins such as ubiquinone (coenzyme Q10), pangamic acid, dimethylglycine, taestrile, amygdaline, flavanoids, para- aminobenzoic acid, adenine, adenylic acid, and s-methylmethionine.
- Minerals in accordance with the embodiments of the sweetener composition of the invention include bulk minerals required in large amounts or trace minerals needed in relatively small amounts.
- the bulk minerals include calcium, chlorine, magnesium, phosphorous, potassium, sodium, iodine and sulphur; whereas the trace minerals include chromium, cobalt, copper, fluorine, iron, manganese, molybdenum, selenium, zinc, bismuth, boron, lithium, nickel, rubidium, silicon, strontium, tellurium, tin, titanium, tungsten, and vanadium.
- the minerals may be in their ionic form or in their molecular form.
- the vitamins or minerals are present in the concentration range up to 10% by weight of the total composition. According to an embodiment, the vitamins or minerals are present in a concentration range up to 5% by weight of the total composition. According to another embodiment, the vitamins or minerals are present in a concentration of at least 0.1% by weight of the total composition.
- the sweetener composition of the invention is prepared by uniformly mixing one or more low glycemic index nutritive ingredients in a rotary batch mixer or any other suitable instrument to obtain a homogenous mixture. To this mixture, requisite quantity of the glucose oxidase enzyme is added and further mixed to obtain the sweetener composition.
- the composition of the invention can also be prepared in situ by adding the individual components to a non-toxic, edible carrier such as water or food articles for instance puddings, cakes etc.
- the invention relates to a nutraceutical composition for regulating the blood sugar concentration, for controlling diabetes and other related ailments in the human body.
- the nutraceutical composition comprises the sweetener composition which includes the Glucose oxidase (GOD) enzyme in a concentration range of 0.01% - 99.99% by weight of the total composition. It further includes at least one low glycemic index nutritive ingredient with a glycemic index of less than 70. The low glycemic index nutritive ingredient is present in a concentration range of 0.01% - 99.9% by weight of the total composition.
- the low glycemic index nutritive ingredient is either a carbohydrate or a polyol or both.
- the carbohydrates include one or more of saccharides and dietary fibres.
- the invention further relates to modified sugar which includes the sweetener composition which comprises Glucose oxidase (GOD) enzyme and at least one nutritive ingredient.
- the Glucose oxidase enzyme is present in a concentration range of from 0.01% - 99.99% by weight of the total composition.
- the nutritive ingredient has a low glycemic index of less than 70 and is present in a concentration range of from 0.01% - 99.9 % by weight of the total composition.
- the invention relates to an article of food which includes the sweetener composition which comprises Glucose oxidase (GOD) enzyme and at least one nutritive ingredient.
- the Glucose oxidase enzyme is present in a concentration range of from 0.01% - 99.99% by weight of the total composition.
- the low glycemic index nutritive ingredient has a low glycemic index of less than 70 and is present in a concentration range of from 0.01% - 99.9 % by weight of the total composition.
- the sweetener composition can be used as a table sweetener in place of sugar or other commonly known sweeteners or can be added to various oral or food compositions for improving the sweetness therein in a healthy manner.
- the sweetener composition of the invention is low on calories, at par on sweetness when compared to sugar and has good after taste rendering it particularly useful for inclusion in food articles in which sweetness increases their taste while avoiding all the drawbacks associated with sugars and all other known sweetener compositions which have a high glycemic index. Furthermore, the sweetener composition mitigates the drawbacks associated with known sweetener compositions in terms of unpleasant aftertastes or long lingering sweetness.
- sugar-like characteristic As used herein, the phrases “sugar-like characteristic,” “sugar-like taste,” “sugarlike sweet,” “sugary,” and “sugar-like” are synonymous.
- Sugar-like characteristics include any characteristic similar to that of sucrose and include, but are not limited to, maximal response, flavour profile, temporal profile, adaptation behaviour, mouthfeel, concentration/response function, taste/and flavour/sweet taste interactions, spatial pattern selectivity, and temperature effects. Of these, however, the flavour profile and temporal profile are particularly important.
- the food products in which the sweetener compositions are used include but are not limited to fruit juices; vegetable juices; fruit beverages; beverages such as tea, coffee, etc; cola drinks; ginger ales; soda waters; other carbonated beverages; health drinks; energy drinks; soft drinks; cocoa; lactic acid bacteria beverages; milk beverages and other general beverages; yogurt; jellies; puddings; cakes; mousse and other desserts; sweet; baked confections; steamed confections; ice creams; sherbets; cold sweets and other ice confectioneries; chewing gums; hard candies; nougat candies; jelly beans; other general confections; fruit flavoured sauces; chocolate sauce and similar sauces; jams; marmalades; breads; ketchups; pouched or packaged or snack foods; instant or ready-to-eat food products; pickles; frozen foods and wide range of processed farm and aquatic products.
- the invention is useful to fortify variety of food ingredients like rice, wheat flour, lentils, spices, edible oils, salt etc appropriately to enhance the nutritional value of the ingredients and improve metabolism of carbohydrates.
- the composition can be added to processed foods and beverages, snack foods, ready to eat and cooked foods etc as well other than its usage in herbal and pharmaceutical product formulations.
- the sweetener composition used in these oral or food products is in an amount which is effective to give the desired sweetness to the food product, and is without any specific limitation.
- the sweetness is variable depending on the kind of the food product in which the sweetener composition is added.
- the dosage is further dependent on other components contained in the food product composition and on the level of sweetness desired by an individual and such other factors.
- the taste or the sweetness profile of the sweetener composition as compared to sugars or other known natural sweeteners is determined by an expert panel who tastes compositions comprising sugar, other natural sweeteners and compositions comprising the Glucose oxidase enzyme in accordance with the embodiment of the present invention, and provide their conclusions as to the similarities of the characteristics of the compositions containing the glucose oxidase enzyme with other sweeteners or sugar.
- the sweetener composition is in a solid or liquid form.
- the solid form includes powder, pill, crystals or tablets.
- the liquid forms include syrup, elixirs or suspension.
- the sweetener composition is used in at least one of a food composition, beverages and nutraceutical composition.
- a further embodiment of the invention relates to a method of regulating or controlling diabetes or blood sugar concentrations in diabetic individuals or persons susceptible to diabetes.
- the method involves administering the nutraceutical composition comprising Glucose oxidase (GOD) enzyme and, at least one low glycemic index nutritive ingredient with a glycemic index of less than 70 to a person suffering from, or susceptible to diabetes.
- the nutraceutical composition is administered in an amount sufficient to lower the blood sugar concentration.
- the nutraceutical composition is in the form of suitable for oral administration such as a liquid, a tablet, a granule or a powder.
- the inventive nutraceutical composition may be administered either in a single dosage, preferably before the breakfast meal in the morning, or in divided doses, i.e., twice daily or three times daily, preferably before each meal.
- the inventive composition may be administered in the form of a preformed capsule or a tablet or it may be incorporated in an edible food stuff such as biscuits, etc.
- the invention further relates to the use of a nutraceutical comprising Glucose oxidase (GOD) enzyme and at least one low glycemic index compound for the controlling hyperglycemia, hypoglycemia, weight loss, obesity, oxidative stress, hyperuricemia , ketoacidosis, nonketotic hyperosmolar coma, cardiovascular diseases, heart stroke, nephropathy, microalbuminuria, insulin resistance, amyloid, foot ulcers, diabetic retinopathy, nonproliferative diabetic retinopathy, proliferative diabetic retinopathy, diabetic macular edema, cataract, glaucoma, high blood cholesterol (HDL) and LDL, triglycerides, atherosclerosis, hypertension, metabolic disorders, constipation, inflammatory bowel disease, ulcerative colitis, Crohn's disease, diverticulitis, neuropathy, coeliac disease, hypothyroidism, hyperthyroidism, polycystic a
- the nutraceutical composition of the invention is prepared by uniformly mixing one or more low glycemic index compounds in a rotary batch mixer or any other suitable instrument to obtain a homogenous mixture. To this mixture, requisite quantity of the glucose oxidase enzyme is added and further mixed to obtain the nutraceutical composition.
- the invention further relates to use of a nutraceutical composition comprising Glucose oxidase (GOD) enzyme and the low glycemic index compound for the treatment of non-diabetic ailments such as cognitive dysfunction, Alzheimer's symptoms and Parkinson's disease.
- GOD Glucose oxidase
- the invention further relates to a pharmaceutical composition which includes the Glucose oxidase (GOD) enzyme and at least one low glycemic index nutritive ingredient with a glycemic index of less than 70.
- GOD Glucose oxidase
- the glucose oxidase enzyme is present in a concentration range of 0.01 to 99.99% by weight of the pharmaceutical composition.
- the Glucose oxidase (GOD) enzyme is present in a concentration range of 0.1% to 40% by total weight of the pharmaceutical composition.
- the Glucose oxidase (GOD) enzyme is present in a concentration range of 0.5% to 20% by total weight of the pharmaceutical composition.
- the Glucose oxidase (GOD) enzyme is present in a concentration range of 1% to 10% by total weight of the pharmaceutical composition.
- the pharmaceutical composition further includes a low glycemic index nutritive ingredient which is selected from one or more of carbohydrates, polyols and sugar alcohols.
- the low glycemic index nutritive ingredient is present in a concentration range of 0.01% - 99.9% by total weight of the pharmaceutical composition.
- the low glycemic index nutritive ingredient is present in a concentration range of 0.1% to 90% by weight of the total composition.
- the low glycemic index nutritive ingredient is present in a concentration range of 1% to 60% by weight of the total composition.
- the low glycemic index nutritive ingredient is present in a concentration range of 1% - 30% by weight of the total composition.
- the low glycemic index nutritive ingredient is present in a concentration range of 1% - 15% by weight of the total composition. According to yet another embodiment, the low glycemic index nutritive ingredient is present in a concentration range of 1% - 10% by weight of the total composition. According to an embodiment, the low glycemic index nutritive ingredient includes one or more of carbohydrate and polyols or sugar alcohols. The carbohydrates are selected from one or more of dietary fibres and saccharides.
- the low glycemic index nutritive ingredient has a glycemic index of not more than 60. More preferably, the low glycemic index nutritive ingredient has a glycemic index of not more than 50.
- Non-limiting examples of dietary fibres used in accordance with the pharmaceutical composition include one or more of non-starch polysaccharides, methylcellulose, ⁇ -glucans, mucilage, waxes, cyclodextrins, celluloses, hemicelluloses, starches, dextrins, inulins, lignins, chitins, pectins, beta-glucans (from oat bran, whole oats, oatrim or rolled oats, whole grain or dry-milled barley), fibres extracted from legumes, Chitosan, natural gums, xanthan gum, guar gum, gellan gum, tara gum, gum acacia, gum arabic, beta-mannan, locust bean gum (carob), psylium seed husk gum, galactomannan, glucomannan or konjac, galactomannan, karaya, tragacanth, hexoses, pento
- the dietary fibres used in accordance with the pharmaceutical composition includes at least one of inulin, galactomannan, beta glucan, fibres extracted from legumes, grains, oats, all types of fruits, vegetables and flaxseeds.
- the dietary fibres also include Inulins (Oligofructose) from chicory root, pectin from apples, guava, citrus fruits and sunflower heads.
- the dietary fibres are present in a concentration range of 0.01% to 99.9% by total weight of the pharmaceutical composition. According to an embodiment, the dietary fibres are present in a concentration range of 0.1% to 80% by total weight of the pharmaceutical composition. According to an embodiment, the dietary fibres are present in a concentration range of 0.1% to 60% by total weight of the pharmaceutical composition. According to an embodiment, the dietary fibres are present in a concentration range of 0.1% to 40% by total weight of the pharmaceutical composition. According to an embodiment, the dietary fibres are present in a concentration range of 0.1% to 20% by total weight of the pharmaceutical composition. According to an embodiment, the dietary fibres are present in a concentration range of 0.1% to 10% by weight of the total composition.
- the polyol or sugar alcohols used in accordance with the pharmaceutical composition include one or more of mannitol, xylitol, maltitol, isomalt, inositol, eiythritol, lactitol, glycerol (glycerine), sorbitol, arabitol, ribitol, polyglycetol, hydrogenated starch hydrolysates (HSH), threitol, fruitol, iditol, volemitol, lactitol, galactitol, palatinose, palatinit, propylene glycol, reduced isomalto-oligosaccharides, fructo-oligosaccharide, maltooligosaccharide, fructo- oligosaccharide, maltooligosaccharide, reduced xylo-oligosaccharides, reduced gentio-oligosaccharides, reduced maltose syrup
- the polyols or sugar alcohols are preferably selected from at least one of mannitol, xylitol, maltitol, erythritol, inositol, isomalt and glycerol.
- the polyols or sugar alcohols are present in a concentration range of 0.01% to 99.9% by total weight of the pharmaceutical composition.
- the polyols or sugar alcohols are present in a concentration range of 0.1% to 60% by total weight of the pharmaceutical composition.
- the polyols or sugar alcohols are present in a concentration range of 0.1% to 30% by total weight of the pharmaceutical composition.
- the polyols or sugar alcohols are present in a concentration range of 0.1% to 10% by total weight of the pharmaceutical composition. According to an embodiment, the polyols or sugar alcohols are present in a concentration range of 0.1% to 5% by total weight of the pharmaceutical composition.
- the saccharide used in accordance with the pharmaceutical composition includes one or more of fructose, glucose, galactose, sucrose, lactose, trehalose, caramel, golden syrup, refiners syrup, blackstrap molasses, maple syrup, honey, sorghum syrup, cane juice, barley malt syrup, coconut palm sugar, brown rice syrup, agave syrup and derivatives thereof.
- Non limiting examples of saccharides include tagatose, rhamnose, dextrin including cyclodextrin such as a-cyclodextrin, ⁇ -cyclodextrin, and ⁇ -cyclodextrin), maltodextrin (including resistant maltodextrins such as Dietary fibersol-2TM), dextran, ribulose, threose, arabinose, xylose, lyxose, allose, altrose, mannose, idose, levulose, hexulose, maltose, invert sugar, isotrehalose, neotrehalose, palatinose or isomaltulose, erythrose, deoxyribose, gulose, idose, talose, erythrulose, xylulose, psicose, turanose, cellulose, cellobiose, starch, pectins such as amylopec
- the saccharides are present in a concentration range of 0.01% to 99.9% by total weight of the pharmaceutical composition. According to another embodiment, the saccharides are present in a concentration range of 1% to 80% by total weight of the pharmaceutical composition. According to another embodiment, the saccharides are present in a concentration range of 1% to 60% by total weight of the pharmaceutical composition. According to another embodiment, the saccharides are present in a concentration range of 1% to 40% by total weight of the pharmaceutical composition. According to another embodiment, the saccharides are present in a concentration range of 1% to 20% by total weight of the pharmaceutical composition.. According to another embodiment, the saccharides are present in a concentration range of 1% to 10% by total weight of the pharmaceutical composition. According to another embodiment, the saccharides are present in a concentration range of 1% to 5% by total weight of the pharmaceutical composition.
- the invention further relates to the use of the pharmaceutical composition for controlling hyperglycemia, hypoglycemia, weight management challenges, obesity, oxidative stress, hyperuricemia , ketoacidosis, non-ketotic hyperosmolar coma, cardiovascular disease, heart stroke, nephropathy, microalbuminuria, insulin resistance, amyloid foot ulcers, diabetic retinopathy, nonproliferative diabetic retinopathy, proliferative diabetic retinopathy, diabetic macular edema, cataract, glaucoma, High blood cholesterol (HDL) and LDL, triglycerides, atherosclerosis, hypertension, metabolic disorders, constipation, inflammatory bowel disease, ulcerative colitis, Crohn's disease, diverticulitis, neuropathy, coeliac disease, hypothyroidism, hyperthyroidism, polycystic ovarian syndrome, diabetes insipidus, necrobiosis lipoidica diabeticorum, mastopathy, limited joint mobility
- the pharmaceutical composition can be administered in various forms including solid, liquid or semi-solid forms.
- the solid forms include granules, powders, tablets, pills, capsules or gel-capsules.
- the liquid forms include syrups, elixirs and liquid solutions or suspensions.
- the semi-solid forms may include gels or pastes.
- the pharmaceutical active ingredient is selected from one or more of antacids, reflux suppressants, antiflatulents, antidopaminergics, proton pump inhibitors, cytoprotectants, prostaglandin analogues, laxatives, antispasmodics, antidiarrhoeals, bile acid sequestrants, opioids, beta-receptor blockers, calcium channel blockers, diuretics, cardiac glycosides, antiarrhythmics, nitrates, antianginals, vasoconstrictors, vasodilators, peripheral activators, ACE inhibitors, angiotensin receptor blockers, alpha blockers, anticoagulants, heparin, antiplatelet drugs, fibrinolytics, anti-hemophilic factors, haemostatic drugs, hypolipidaemic agents, statins, hynoptics, anaesthetics, antipsychotics, antidepressants, antiemetics, anticonvulsants, antiepileptics, anxi
- the invention also relates to a method of treatment of diseases including hyperglycemia, hypoglycemia, weight management challenges, obesity, oxidative stress, hyperuricemia , ketoacidosis, non-ketotic hyperosmolar coma, cardiovascular disease, heart stroke, nephropathy, microalbuminuria, insulin resistance, amyloid foot ulcers, diabetic retinopathy, nonproliferative diabetic retinopathy, proliferative diabetic retinopathy, diabetic macular edema, cataract, glaucoma, High blood cholesterol (HDL) and LDL, triglycerides, atherosclerosis, hypertension, metabolic disorders, constipation, inflammatory bowel disease, ulcerative colitis, Crohn's disease, diverticulitis, neuropathy, coeliac disease, hypothyroidism, hyperthyroidism, polycystic ovarian syndrome, diabetes insipidus, necrobiosis lipoidica diabeticorum, mastopathy, limited joint mobility
- diseases including
- GOD Glucose oxidase enzyme
- compositions of samples I to VI are glucose oxidase compositions.
- Compositions of samples VII and VIII are prepared for comparisons only.
- Sample I was prepared by uniformly mixing 500 gms of Inulin and 495 gms of Galactomannan obtained from fenugreek, in a rotary batch mixer at 24 degrees Celsius. To this mixture, 5 gms of glucose oxidase enzyme was added and further mixed to obtain a sweetener composition containing 0.5% of Glucose oxidase enzyme, 50% of Inulin and 49.5% of Galactomannan
- Samples II to VIII were prepared as per the process of preparation of Sample 1 wherein the samples included Glucose Oxidase Enzyme in combination with one or more of inulin, beta glucan, galactomannan from Fenugreek and Wheat bran fibre in concentrations as set forth in Table 1
- compositions containing Glucose oxidase enzyme (GOD) and + polyols mannitol, erythritol, sorbitol and xylitol:
- compositions of samples I to VIII are glucose oxidase compositions.
- Composition of samples IX is prepared for comparisons only.
- Sample I was prepared by uniformly mixing 300 gms of mannitol, 300 gms of Erythritol and 395 gms of sorbitol in a rotary batch mixer at 24 degrees Celsius. To this mixture, 5 gms of glucose oxidase enzyme was added and further mixed to obtain a sweetener composition containing 0.5% of Glucose oxidase enzyme, 30% of Mannitol, 30% Erythritol and 39.5 of sorbitol.
- Samples II to IX were prepared as per the process of preparation of Sample 1 wherein the samples included Glucose Oxidase Enzyme in combination with one or more of mannitol, erythritol, sorbitol and xylitol in concentrations, as set forth in Table 2.
- compositions of samples I to VIII are glucose oxidase compositions.
- Composition of samples IX is prepared for comparisons only.
- Sample I was prepared by uniformly mixing 450 gms of fructose and 545 gms of dextrin in a rotary batch mixer at 24 degrees Celsius. To this mixture, 5 gms of glucose oxidase enzyme was added and further mixed to obtain a sweetener composition containing 0.5% of Glucose oxidase enzyme, 45% of Fructose and 54.5% of dextrin.
- Samples II to IX were prepared as per the process of preparation of Sample 1 wherein the samples included Glucose Oxidase Enzyme in combination with one or more of Fructose, sucrose, dextrin, lactose and Tagatose in concentrations, as set forth in Table 3.
- compositions containing Glucose oxidase enzyme (GOD), dietary fibres (inulin or beta glucan) and polyols or sugar alcohols (mannitol or erythritol)
- GOD Glucose oxidase enzyme
- dietary fibres inulin or beta glucan
- polyols or sugar alcohols mannitol or erythritol
- compositions of samples I to VII are glucose oxidase compositions.
- Composition of samples VIII is prepared for comparisons only. To this mixture, 5 gms of glucose oxidase enzyme was added and further mixed to obtain a sweetener composition containing 0.5% of Glucose oxidase enzyme, 45% of inulin, 31% of mannitol and 3.5% of erythritol.
- Samples II to VIII were prepared as per the process of preparation of Sample 1 wherein the samples included Glucose Oxidase Enzyme in combination with one or more of inulin and beta glucan and one or more of mannitol and erythritol in concentrations, as set forth in Table 4.
- Example 5 Compositions containing Glucose oxidase enzyme (GOD), dietary fibres (inulin or beta glucan) and saccharides (sucrose or sea weed derived polysaccharides)
- GOD Glucose oxidase enzyme
- dietary fibres inulin or beta glucan
- saccharides saccharides
- compositions of samples I to VII are glucose oxidase compositions.
- Composition of samples VIII is prepared for comparisons only.
- Sample I was prepared by uniformly mixing 20 gms of inulin, 940 gms of sucrose and 35 gms of Sea weed based polysaccharides in a rotary batch mixer at 24 degrees Celsius to obtain a mixture.
- 5 gms of glucose oxidase enzyme was added and further mixed to obtain a sweetener composition containing 0.5% of Glucose oxidase enzyme, 2% of inulin, 94% of sucrose and 3.5% of the Tagatose.
- Samples II to VIII were prepared as per the process of preparation of Sample 1 wherein the samples included Glucose Oxidase Enzyme in combination with one or more of inulin and beta glucan and one or more of sucrose and tagatose in concentrations, as set forth in Table 5.
- compositions containing Glucose oxidase enzyme (GOD), polyols such as mannitol or erythritol and saccharides such as sucrose or sea weed derived polysaccharides.
- GOD Glucose oxidase enzyme
- polyols such as mannitol or erythritol
- saccharides such as sucrose or sea weed derived polysaccharides.
- Table 6 Sweetener compositions
- compositions of samples I to VII are glucose oxidase compositions.
- Composition of samples VIII is prepared for comparisons only.
- Sample I was prepared by uniformly mixing 10 gms of mannitol, 10 gms of erythritol, 950 gms of sucrose and 25 gms of Sea weed based polysaccharides in a rotary batch mixer at 24 degrees Celsius to obtain a mixture.
- 5 gms of glucose oxidase enzyme was added and further mixed to obtain a sweetener composition containing 0.5% of Glucose oxidase enzyme, 1% of mannitol, 1% of erythritol, 95% of sucrose and 2.5% of tagatose.
- Samples II to VIII were prepared as per the process of preparation of Sample 1 wherein the samples included Glucose Oxidase Enzyme in combination with one or more of mannitol and erythritol one or more of sucrose and tagatose in concentrations, as set forth in Table 6.
- compositions containing Glucose oxidase enzyme (GOD), dietary fibres such as inulins and betaglucans, polyols such as mannitol or erythritol and saccharides such as sucrose or tagatose Table 7: Sweetener compositions
- compositions of samples I to VII are glucose oxidase compositions.
- Composition of samples VIII is prepared for comparisons only.
- Sample I was prepared by uniformly mixing 50 gms of inulin, 10 gms of mannitol, 40 gms of erythritol, 800 gms of sucrose and 95 gms of Sea weed based polysaccharides in a rotary batch mixer at 24 degrees Celsius to obtain a mixture.
- glucose oxidase enzyme was added and further mixed to obtain a sweetener composition containing 0.5% of Glucose oxidase enzyme, 5% inulin, 1% of mannitol, 4% of erythritol, 80% of sucrose and 9.5% of tagatose.
- Samples II to VIII were prepared as per the process of preparation of Sample 1 wherein the samples included Glucose Oxidase Enzyme in combination with one or more of inulin and beta glucan; one or more of mannitol and erythritol, one or more of sucrose and sea weed based polysaccharides in concentrations, as set forth in Table 7.
- Example 8 Preparation example of Nutraceutical and Sweetener compositions modified containing the glucose oxidase enzyme based sweetener compositions:
- Modified sugar as per the sample A was prepared by blending thoroughly all the ingredients as per table 8 in a Nauta mixer or Rotary octagonal blender for 30 mins. The blending is preferably done in an air conditioned room where temperature is less than 24°C and R.H. is less than 40%.
- Other samples B-K for the modified sugar were prepared following the process similar to Sample A. Samples E and F are not as sweet as other samples. Hence at least 50 % sweetening agent is desired for modified sugar.
- a method of evaluation is provided as follows. In this method, none of the samples were swallowed. All samples were expectorated and the mouth was rinsed with water after the tasting. All the samples were tasted by distributing 10 ml of the sample quickly throughout the oral cavity and sweetness intensity was measured. This intensity was measured on a scale of 0-5 where 0 is defined as no perceptible sweetness and 5 was defined as the sweetness of sugar. When maximum sweetness was experienced, the sample was expectorated and the mouth was rinsed with water and rate of "Sweetness Linger" was measured, at 3-4 mins after the water rinse.
- Splenda (Sucralose + About 600 3 Linge 4
- samples 1 and 2 containing glucose oxidase enzyme prepared as per the embodiment of the present invention exhibits a sweetness index of 5 and tastes exactly similar to that of sugar as compared to Sample 3 containing glucose and Samples 4 and 5 which include artificial sweeteners such as Splenda, which is a Sucralose containing sweetener and Acesulfame K, or Sample 6 which include natural sugar substitute such as Stevia, respectively.
- artificial sweeteners such as Splenda, which is a Sucralose containing sweetener and Acesulfame K, or Sample 6 which include natural sugar substitute such as Stevia, respectively.
- these artificial sweeteners are 30-200 times more sweeter as compared to that of sugar.
- Table 11 Effect of compositions of present invention on body weight and muscle mass Sr. Example Dose Initial Body Muscle mass
- the sweetener or the nutraceutical compositions containing the glucose oxidase enzyme as per the embodiment of the present invention helps in maintaining the body weight of an individual as compared to sugar or other known sweeteners.
- Example 11 Known sweetener compositions based on artificial sweeteners such as sucralose or Acesulfame K along with natural sugar substitute compositions including stevia, sugar, glucose and sucrose, were compared with the sweetener or the nutraceutical compositions containing glucose oxidase enzyme for their calorific values. The calorific values are determined using Bomb Calorimeter. The results observed were tabulated as follows:
- Table 12 Calories per 100 g of glucose oxidase compositions and sweetener compositions of present invention and sugars and other reported / marketed compositions
- the sweetener or the nutraceutical compositions 1-3 containing the glucose oxidase enzyme as per the embodiments of the present invention are beneficial in terms of reducing the daily calories consumed by an individual, as compared to other artificial sweetener compositions based on Sucralose or Acesulfame K or even other natural sugar substitute based sweetener compositions including Stevia or with consumption of glucose or table sugar, indicating that the compositions as per the embodiment of the present invention are highly suitable for diet conscious individuals.
- Examplel2 Compositions containing Glucose oxidase enzyme (GOD), dietary fibres (inulin or beta glucan) and polyols or sugar alcohols (mannitol or erythritol)
- GOD Glucose oxidase enzyme
- dietary fibres inulin or beta glucan
- polyols or sugar alcohols mannitol or erythritol
- the glucose oxidase enzyme, Inulin and Beta glucan are thoroughly mixed to get a uniform blend. 2. To the blended mixture mannitol and erythritol are added and uniformly mixed to get the desired composition.
- Example 13 Comparison of food article such as pudding containing i. sweetener composition with Glucose oxidase enzyme as per the embodiments of the present invention; ii Artificial sweetener (sucralose) based compositions iii. Natural sugar substitute based compositions and iv. Compositions containing low intensity sweeteners such as xylitol in terms of calorific values and blood sugar levels. The results observed were tabulated as follows:
- Table 14 Effect of food compositions of present invention on body weight and blood sugar levels of borderline cases
- Example 14 Six diabetic type 2 patients were randomly administered known sweeteners such as Sucralose and Stevia along with the sweetener or the nutraceutical composition containing glucose oxidase enzyme, as per the present invention, for their effect on the blood sugar concentration levels.
- sweeteners such as Sucralose and Stevia along with the sweetener or the nutraceutical composition containing glucose oxidase enzyme, as per the present invention, for their effect on the blood sugar concentration levels.
- Table 15 Sweetener composition effect on blood sugar levels Sr. Example Dose per day Blood sugar Blood sugar
- Example 15 The pharmaceutical or nutraceutical composition containing glucose oxidase enzyme as per the present invention, Sucralose or stevia based sweetener composition and other known sweeteners and antidiabetic drugs based on sulphonylureas and biguanides were given to 3 diabetic patients (Hyperglycemics & Hyperlipidaemic patients) with an advice to replace it totally for Sugar and their blood sugar levels were monitored for a period of 6 months.
- Known pharmaceutical/nutraceutical compositions as well as other artificial sweeteners were compared to the pharmaceutical composition including the glucose oxidase enzyme of the invention for controlling oxidative stress in diabetic individuals.
- Micronucleus is a small nucleus (also known as erratic or third nucleus), present in the cytoplasm of the cell. Formation of micronuclei indicates oxidative stress and genetic damage.
- the micronucleus assay using scraped buccal epithelial cells is an easy and non-invasive assay to estimate oxidative stress.
- compositions 1 and 2 there is a surprisingly high reduction in the oxidative stress values after with the administration of the nutraceutical or the pharmaceutical composition comprising the glucose oxidase enzyme (compositions 1 and 2) as per the embodiment of the pending application as compared to the reduction observed with the conventional antidiabetic drugs.
- compositions 1 and 2 there is an increase in the oxidative stress values with the consumption of artificial sweeteners compositions including stevia or sucralose or with the consumption of sugar.
- Example 17 The HbAlc Values of diabetic individuals were monitored after administration of known diabetic drugs (sulphonyl urea or Biguanides), with the administration of insulin, and with the administration of a pharmaceutical or nutraceutical compositions containing glucose oxidase enzyme, as per the embodiment of the present invention. Comparisons were also made with Sucralose or stevia based sweetener composition and other known sweeteners. The observations are set forth in the table below. The HbAlc Values of these diabetic individuals were monitored over a period of 3 months, 6 months and 12 months respectively.
- known diabetic drugs sulphonyl urea or Biguanides
- HbAlc is a lab test that measures the number of glucose molecules attached to haemoglobin, whereby the test gives a better average of blood sugar management with diabetics since it is averaged over 2 - 3 months, in contrast to the daily high/ low glucose fluctuations when measuring blood sugar.
- Example 18 Observations in the blood triglyceride levels and cholesterol levels of diabetic individuals were made after the consumption of the pharmaceutical or nutraceutical composition containing glucose oxidase enzyme, as per the embodiment of the present invention and in comparison to known artificial sweeteners such as sucralose or sweeteners based on natural sugar substitute such as stevia. The observations are set forth in the table below:
- compositions 1 and 2 as per the embodiments of the invention as compared to compositions 3-5 with known sweeteners.
- the compositions containing the glucose oxidase enzyme as per the embodiments of the present invention can be used in humans to eliminate their dependence on diabetic drugs and thereby obviate the side effects shown by such drugs.
- compositions 1-4 containing Glucose Oxidase Enzyme administered to patients with Hyperglycemia for the period upto 90 days. Their body weights were also monitored.
- Composition 25 178 145 128 76 71
- composition 25 160 150 130 80 74
- compositions 1 to 4 wherein, prepared as per the embodiments of the invention as compared to consumption of known artificial sweetener sucralose (refer table 15, composition 5), and also sweetener compositions which are based on Stevia (refer table 15, composition 4).
- Compositions A to D prepared in accordance with the present invention lead to 6 8% weight loss in 3 months without any adverse side effects observed.
- sweetener composition of the present invention is found to be best suitable for Diabetics.
- Artificial sweetener, sucralose respond almost in the same manner as that of Glucose.
- Most of the artificial sweeteners use Glucose / Dextrose monohydrate as the bulking agent which has glycemic index of 100 or more.
- the tablets were prepared by geometrically mixing the ingredients and compressed using direct compression method.
- the Gliclazide, Lactose, glucose oxidase enzyme, inulin, beta glucan, pectin and Sodium Starch Glycolate are thoroughly mixed and the magnesium stearate and Talc are added and mixed before the compression process.
- compositions containing glucose oxidase enzyme as per the embodiments of the present invention appear to alleviate the effects of known antidiabetic drugs in lowering the blood sugar concentrations. It is observed that when composition of the invention is ingested or administered it co-acts with the insulin normally present in the body to reduce blood sugar concentrations by direct oxidation of glucose or by increasing the speed of the entire metabolic carbohydrate degradation process and by maintaining the insulin in its R-S-S-R active cysteinic form as opposed to the R-SH cysteine form which is inactive.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3032926A CA3032926A1 (en) | 2016-08-09 | 2017-08-08 | Novel glucose oxidase compositions |
EP17838941.7A EP3497210A4 (en) | 2016-08-09 | 2017-08-08 | Novel glucose oxidase compositions |
CN201780056059.4A CN109844106A (en) | 2016-08-09 | 2017-08-08 | Novel grape oxidase composition |
US16/324,089 US11202821B2 (en) | 2016-08-09 | 2017-08-08 | Glucose oxidase compositions |
AU2017309850A AU2017309850A1 (en) | 2016-08-09 | 2017-08-08 | Novel glucose oxidase compositions |
US17/555,262 US20220111014A1 (en) | 2016-08-09 | 2021-12-17 | Novel glucose oxidase compositions |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201621027241 | 2016-08-09 | ||
IN201621027241 | 2016-08-09 | ||
PCT/IN2017/000084 WO2018029698A1 (en) | 2016-08-09 | 2017-04-17 | Novel nutraceutical composition |
INPCT/IN2017/000084 | 2017-04-17 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/324,089 A-371-Of-International US11202821B2 (en) | 2016-08-09 | 2017-08-08 | Glucose oxidase compositions |
US17/555,262 Division US20220111014A1 (en) | 2016-08-09 | 2021-12-17 | Novel glucose oxidase compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018029705A1 true WO2018029705A1 (en) | 2018-02-15 |
Family
ID=61162813
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2017/050332 WO2018029705A1 (en) | 2016-08-09 | 2017-08-08 | Novel glucose oxidase compositions |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2018029705A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2702010C1 (en) * | 2018-11-08 | 2019-10-03 | Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия непрерывного профессионального образования" Министерства здравоохранения Российской Федерации (ФГБОУ ДПО РМАНПО Минздрава России) | Method of treating diffuse benign breast dysplasia |
CN111593034A (en) * | 2020-06-24 | 2020-08-28 | 江南大学 | Method for preparing gentiooligosaccharide by using beta-1, 6-glucanase and application thereof |
US11185080B2 (en) | 2014-04-30 | 2021-11-30 | Matoke Holdings Limited | Antimicrobial compositions |
CN114591843A (en) * | 2022-03-01 | 2022-06-07 | 北京建筑大学 | Solid culture medium of coriolus versicolor, preparation method and application |
US11730168B2 (en) | 2017-10-16 | 2023-08-22 | Matoke Holdings Limited | Antimicrobial superabsorbent compositions |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7892536B2 (en) * | 2006-12-20 | 2011-02-22 | Daniso US Inc. | Storage-stable glucose oxidase |
-
2017
- 2017-08-08 WO PCT/IN2017/050332 patent/WO2018029705A1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7892536B2 (en) * | 2006-12-20 | 2011-02-22 | Daniso US Inc. | Storage-stable glucose oxidase |
Non-Patent Citations (4)
Title |
---|
AKHILA JS , DIVYA C, REJEESH, VINOD N, MARIA K ET AL.: "Effect of the insulin plant (Costus igneus) leaves on dexamethasone-induced hyperglycemia", INT J AYURVEDA RES, vol. 1, 2010, pages 100 - 102, XP055463454 * |
FAIYAZ AHMED ET AL.: "In vitro hypoglycemic effects of selected dietary fiber sources", J FOOD SCI TECHNOL., vol. 48, no. 3, June 2011 (2011-06-01), pages 285 - 289, XP055463457 * |
MARIANA MONTI ET AL.: "Starch and fiber intake and glucose postprandial response of dogs", CIENC. RURAL, vol. 46, no. 2, February 2016 (2016-02-01), Santa Maria, pages 354 - 361, XP055463450 * |
See also references of EP3497210A4 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11185080B2 (en) | 2014-04-30 | 2021-11-30 | Matoke Holdings Limited | Antimicrobial compositions |
US11311017B2 (en) | 2014-04-30 | 2022-04-26 | Matoke Holdings Limited | Antimicrobial compositions |
US11730168B2 (en) | 2017-10-16 | 2023-08-22 | Matoke Holdings Limited | Antimicrobial superabsorbent compositions |
RU2702010C1 (en) * | 2018-11-08 | 2019-10-03 | Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия непрерывного профессионального образования" Министерства здравоохранения Российской Федерации (ФГБОУ ДПО РМАНПО Минздрава России) | Method of treating diffuse benign breast dysplasia |
CN111593034A (en) * | 2020-06-24 | 2020-08-28 | 江南大学 | Method for preparing gentiooligosaccharide by using beta-1, 6-glucanase and application thereof |
CN114591843A (en) * | 2022-03-01 | 2022-06-07 | 北京建筑大学 | Solid culture medium of coriolus versicolor, preparation method and application |
CN114591843B (en) * | 2022-03-01 | 2023-05-30 | 北京建筑大学 | Solid medium for coriolus versicolor as well as preparation method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11202821B2 (en) | Glucose oxidase compositions | |
WO2018029705A1 (en) | Novel glucose oxidase compositions | |
Ghosh et al. | A review on polyols: new frontiers for health-based bakery products | |
AU2003245923B2 (en) | Galactosyl isomalt, method for production and use thereof | |
EP3402338B1 (en) | Low carbohydrate sugar fondant | |
DE10262018B4 (en) | Compositions, foodstuffs, food and beverages, confectionery, animal feed, dietary special nutrition, child nutrition, sweeteners and pharmaceutical compositions containing condensed palatinose | |
KR20190029579A (en) | Caramel with short texture | |
TWI303992B (en) | ||
JP2006512298A (en) | Hydrogenated condensed palatinose | |
JP6453897B2 (en) | Slowly digestive sustained energy supplement | |
US20180020701A1 (en) | A natural sweetening composition of luo han guo | |
CA2999387C (en) | Methods for improving the gastrointestinal tolerance of food and beverage products comprising sweet, low-digestible carbohydrates | |
CN107410631A (en) | A kind of multi-functional glycoconjugate and preparation method and application | |
US20200253257A1 (en) | Sugar replacement composition and method of using the same | |
Евсеев | Sweeteners in Diabetes Mellitus Diet | |
a Subgroup | 3.1 Classification of dietary carbohydrates | |
IL165448A (en) | Galactosyl isomalt compositions and methods for producing galactosyl isomalt |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17838941 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3032926 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2017309850 Country of ref document: AU Date of ref document: 20170808 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017838941 Country of ref document: EP Effective date: 20190311 |